Trial Profile
A Randomized, Double-blinded, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of HMS5552 in Adult Patients With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Aug 2023
Price :
$35
*
At a glance
- Drugs Dorzagliatin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Hua Medicine
- 26 Jun 2023 Results assessing effects of dorzagliatin on beta-cell function within all dose group using Oral minimal model presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
- 09 Jun 2015 Results of pooled analysis of two phase I trials presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
- 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.